Search results for "Pars Compacta"

showing 10 items of 30 documents

The neurobiological bases for the pharmacotherapy of nicotine addiction.

2007

Nicotine, the major psychoactive agent present in tobacco, acts as a potent addictive drug both in humans and laboratory animals, whose locomotor activity is also stimulated. A large body of evidence indicates that the locomotor activation and the reinforcing effects of nicotine may be related to its stimulatory effects on the mesolimbic dopaminergic function. Thus, it is now well established that nicotine can increase in vivo DA outflow in the nucleus accumbens and the corpus striatum. The stimulatory effect of nicotine on DA release most probably results from its ability to excite the neuronal firing rate and to increase the bursting activity of DA neurons in the substantia nigra pars com…

RAT STRIATAL SYNAPTOSOMESNicotineINDUCED BEHAVIORAL SENSITIZATIONmedia_common.quotation_subjectSubstantia nigraStriatumNicotinic AntagonistsBiologyNucleus accumbensPharmacologyReceptors NicotinicNicotineDrug DiscoverySUSTAINED-RELEASE BUPROPIONmedicineLOCOMOTOR STIMULANT ACTIONAnimalsHumansNicotinic Agonistsmedia_commonPharmacologyMIDBRAIN DOPAMINE NEURONSPars compactaAddictionNIGRA PARS COMPACTAFACILITATES SMOKING CESSATIONTobacco Use DisorderSUBUNIT MESSENGER-RNAAntidepressive AgentsVentral tegmental areaVENTRAL TEGMENTAL AREANicotinic agonistmedicine.anatomical_structurenervous systemmedicine.drugSEROTONIN(2C) RECEPTORS BLOCKSCurrent pharmaceutical design
researchProduct

Impact of serotonin 2C receptor null mutation on physiology and behavior associated with nigrostriatal dopamine pathway function.

2009

The impact of serotonergic neurotransmission on brain dopaminergic pathways has substantial relevance to many neuropsychiatric disorders. A particularly prominent role has been ascribed to the inhibitory effects of serotonin 2C receptor (5-HT2CR) activation on physiology and behavior mediated by the mesolimbic dopaminergic pathway, particularly in the terminal region of the nucleus accumbens. The influence of this receptor subtype on functions mediated by the nigrostriatal dopaminergic pathway is less clear. Here we report that a null mutation eliminating expression of 5-HT2CRs produces marked alterations in the activity and functional output of this pathway. 5-HT2CR mutant mice displayed i…

medicine.medical_specialtySerotoninDopamineDopamine AgentsPhysiologySubstantia nigraStriatumBiologySettore BIO/09 - FisiologiaPiperazinesArticleMiceDopamine receptor D1Dopamine Uptake InhibitorsDopamineDopamine receptor D2Internal medicineNeural PathwaysmedicineReceptor Serotonin 5-HT2CAnimalsNeuronsBehavior AnimalPars compactaGeneral Neuroscience5-HT2CR substantia nigra pars compacta dorsal striatum dopamine extracellular recording in vivo patch clamp recording microdialysis Locomotor activity Stereotypic behaviorDopaminergicNeurobehavioral disordersBenzazepinesGroomingCorpus StriatumElectrophysiologyMice Inbred C57BLSubstantia NigraAmphetamineEndocrinologymedicine.anatomical_structureDopaminergic pathwaysDopamine AgonistsMutationAutoradiographyStereotyped BehaviorNeuroscienceLocomotionmedicine.drugThe Journal of neuroscience : the official journal of the Society for Neuroscience
researchProduct

Lateral Habenula 5-HT2C Receptor Function Is Altered by Acute and Chronic Nicotine Exposures

2021

Serotonin (5-HT) is important in some nicotine actions in the CNS. Among all the 5-HT receptors (5-HTRs), the 5-HT2CR has emerged as a promising drug target for smoking cessation. The 5-HT2CRs within the lateral habenula (LHb) may be crucial for nicotine addiction. Here we showed that after acute nicotine tartrate (2 mg/kg, i.p.) exposure, the 5-HT2CR agonist Ro 60-0175 (5–640 µg/kg, i.v.) increased the electrical activity of 42% of the LHb recorded neurons in vivo in rats. Conversely, after chronic nicotine treatment (6 mg/kg/day, i.p., for 14 days), Ro 60-0175 was incapable of affecting the LHb neuronal discharge. Moreover, acute nicotine exposure increased the 5-HT2CR-immunoreactive (IR)…

0301 basic medicinenucleus accumbensdorsal raphe nucleusmedicine.medical_treatmentstriatumStriatumSmoking cessationSettore BIO/09 - FisiologiaSerotonin -- ReceptorsNicotineNicotine addiction -- Treatment0302 clinical medicinesingle cell-extracellular recordingMedicinesubstantia nigra pars compactadentate gyrusBiology (General)SpectroscopyGeneral MedicineDorsal raphe nucleuComputer Science ApplicationsVentral tegmental area5-HT2C receptorChemistrymedicine.anatomical_structuredepressionaddictionmedicine.drugAgonistmedicine.medical_specialtyendocrine systemQH301-705.5medicine.drug_classRo 60-0175ventral tegmental areaNucleus accumbensDentate gyruCatalysisInorganic Chemistry03 medical and health sciencesInternal medicineNucleus accumbenPhysical and Theoretical ChemistryQD1-999Molecular BiologyHabenulabusiness.industryOrganic Chemistry030104 developmental biologyEndocrinologySmoking cessationSerotoninbusinessSerotonin -- Agonists030217 neurology & neurosurgerymedial prefrontal cortexInternational Journal of Molecular Sciences
researchProduct

Effects of Substantia Nigra pars compacta lesion on the behavioral sequencing in the 6-OHDA model of Parkinson’s disease

2019

The basal ganglia circuitry plays a crucial role in the sequential organization of behavior. Here we studied the behavioral structure of the animals after 21 days of 6-OHDA-induced lesion of the dopaminergic nigrostriatal system. Frequencies and durations of individual components of the behavioral repertoire were calculated; moreover, whether a temporal organization of the activity was present, it was investigated by using T-pattern analysis, a multivariate approach able to detect the real-time sequential organization of behavior. Six sham-depleted and six rats with unilateral 6−OHDA-lesion of the Substantia Nigra pars compacta were used. As to quantitative evaluations, the comparison betwe…

MaleParkinson's diseaseDopamineParkinson's diseaseSubstantia nigra6-OHDABiologyT-pattern analysisSettore BIO/09 - FisiologiaRats Sprague-DawleyLesion03 medical and health sciencesBehavioral Neuroscience0302 clinical medicineSubthalamic NucleusSniffingDopamineBasal gangliamedicine6-OHDA; Basal ganglia; Dopamine; Parkinson's disease; Substantia Nigra pars compacta; T-pattern analysis; Animals; Behavior Animal; Dopamine; Male; Oxidopamine; Parkinson Disease; Pars Compacta; Rats Sprague-Dawley; Substantia Nigra; Subthalamic NucleusAnimalsOxidopaminePars Compacta030304 developmental biologyBehavior0303 health sciencesBehavior AnimalAnimalPars compactaDopaminergicT-pattern analysiParkinson Diseasemedicine.diseaseRatsSubstantia Nigranervous system6-OHDA; Basal ganglia; Dopamine; Parkinson's disease; Substantia Nigra pars compacta; T-pattern analysis; Behavioral NeuroscienceBasal gangliaSprague-DawleySubstantia Nigra pars compactamedicine.symptomNeuroscience030217 neurology & neurosurgerymedicine.drugBehavioural Brain Research
researchProduct

Nitric Oxide Modulation of the Dopaminergic Nigrostriatal System: Focus on Nicotine Action

2009

Nitric oxide (NO) signalling plays an important role in the integration of information processed by the basal ganglia nuclei. Accordingly, considerable evidence has emerged indicating a role for NO in pathophysiological conditions such as Parkinson’s disease (PD), schizophrenia and drug addiction. To further investigate the NO modulation of dopaminergic function in the basal ganglia circuitry, in this study we used in vivo electrophysiology and microdialysis in freely-moving rats. Pharmacological manipulation of the NO system did not cause any significant changes either in the basal firing rate and bursting activity of the dopamine (DA) neurons in the substantia nigra pars compacta (SNc) or…

Nicotine addictionPars compactaChemistryDopamineDopaminergicNitric oxideSubstantia nigraStriatumSettore BIO/09 - FisiologiaNicotineGlobus pallidusnitric oxideDopaminebasal gangliaBasal gangliamedicinenigrostriatal pathwayNeurosciencedopaminergicnicotinemedicine.drug
researchProduct

Involvement of Nitric Oxide in Nigrostriatal Dopaminergic System Degeneration : A Neurochemical Study.

2009

The present study was undertaken to explore the involvement of nitric oxide (NO) in the 6-hydroxydopamine (6-OHDA) experimental model of Parkinson's disease (PD) in rats. The effect of pharmacological manipulation of the NO system was evaluated on striatal dopamine (DA) level decrease produced by the toxin. 7-nitroindazole (7-NI, 50 mg/kg i.p.; n= 5) pretreatment significantly restored the striatal DA contents. Conversely, 40 mg/kg i.p. of molsidomine (MOL, n= 5), an NO donor, significantly worsened the neurodegeneration (n= 5) and completely counteracted the neuroprotective effect of 7-NI (n= 5). Thus, a crucial role for NO in 6-OHDA induced neurodegeneration is suggested together with a p…

MaleIndazolesMolsidomineParkinson's disease (PD)Substantia nigraPharmacologyNitric OxideNeuroprotectionSettore BIO/09 - FisiologiaGeneral Biochemistry Genetics and Molecular BiologyNitric oxideRats Sprague-Dawleychemistry.chemical_compoundNeurochemicalHistory and Philosophy of ScienceDopaminemedicineAnimalsNitric Oxide DonorsOxidopaminenitric oxide (NO)corpus striatumGeneral Neurosciencesubstantia nigra pars compacta (SNc)Dopaminergic6-hydroxydopamine (6-OHDA)Parkinson DiseaseRatsSubstantia NigrachemistryMolsidomineNeuroscienceOxidopaminemedicine.drug
researchProduct

[18F]PR04.MZ PET/CT Imaging for Evaluation of Nigrostriatal Neuron Integrity in Patients With Parkinson Disease.

2020

Introduction Degeneration of dopaminergic, nigrostriatal neurons is the hallmark of Parkinson disease (PD), and PET quantification of dopamine transporters is a widely accepted method for differential diagnosis between idiopathic PD and essential tremor. [18F]PR04.MZ is a new PET tracer with excellent imaging properties allowing for precise quantification of striatal and extrastriatal dopamine transporter. Here we describe our initial experience with [18F]PR04.MZ PET/CT in a larger cohort of healthy controls and PD patients as a proof-of-concept study for this tracer. Methods Eighteen healthy subjects, 19 early PD patients (Hoehn-Yahr I–II), and 13 moderate-advanced PD patients (Hoehn-Yahr …

MaleDopamineCaudate nucleusPET imagingSubstantia nigra[18F]PR04.MZ030218 nuclear medicine & medical imagingCohort Studies03 medical and health sciences0302 clinical medicineDopaminePositron Emission Tomography Computed TomographyMedicineHumansRadiology Nuclear Medicine and imagingdopamine transporterDopamine transporterAgedNeuronsDopamine Plasma Membrane Transport ProteinsbiologyEssential tremorbusiness.industryPars compactaPutamenDopaminergicParkinson DiseaseGeneral MedicineOriginal ArticlesMiddle Agedmedicine.diseaseSubstantia Nigranervous system030220 oncology & carcinogenesisbiology.proteinmovement disordersFemalebusinessNuclear medicinemedicine.drugClinical nuclear medicine
researchProduct

WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model…

2009

Parkinson's disease (PD) is characterized by the progressive loss of nigrostriatal dopamine neurons leading to motor disturbances and cognitive impairment. Current pharmacotherapies relieve PD symptoms temporarily but fail to prevent or slow down the disease progression. In this study, we investigated the molecular mechanisms by which the non-selective cannabinoid receptor agonist WIN55,212-2 (WIN) protects mouse nigrostriatal neurons from 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity and neuroinflammation. Stereological analyses showed that chronic treatment with WIN (4 mg/kg, intraperitoneal), initiated 24 h after MPTP administration, protected against MPTP-ind…

Agonistmedicine.drug_classbusiness.industryPars compactaGeneral NeuroscienceMPTPCannabinoid Receptor AgonistsSubstantia nigraPharmacologynervous system diseaseschemistry.chemical_compoundnervous systemchemistryDopaminemedicineCannabinoid receptor type 2MPTP Poisoninglipids (amino acids peptides and proteins)businessmedicine.drugEuropean Journal of Neuroscience
researchProduct

Effects of Intraaccumbens Microinjections of Quinpirole on Head Turning and Circling Movement in the Rat

1998

This study was designed to evaluate whether nucleus accumbens dopamine D2 receptors are involved in the initiation of the movement, as distinguished from its execution. For this purpose, the effects of the quinpirole-induced increase of nucleus accumbens dopamine D2 receptor activity were observed on specific parameters of the circling behavior and of its first stage, the head-turning (HT) movement. The experiments were performed on rats with unilateral 6-hydroxydopamine (6-OHDA) lesion of the pars compacta of the substantia nigra and d-amphetamine i.p. (3 mg/kg). Bilateral intraaccumbens microinjections of quinpirole (1, 5, and 10 microg/0.5 microl), an agonist of the D2 receptor family, w…

Malemedicine.medical_specialtyDextroamphetamineQuinpiroleMicroinjectionsClinical BiochemistrySubstantia nigraNucleus accumbensToxicologyBiochemistryNucleus AccumbensBehavioral NeuroscienceQuinpiroleDopamine Uptake InhibitorsDopamine receptor D2Internal medicineBasal gangliamedicineAnimalsRats WistarOxidopamineBiological PsychiatryPharmacologyDose-Response Relationship DrugPars compactaChemistrySympathectomy ChemicalDextroamphetamineBody movementRatsEndocrinologyDopamine AgonistsSympatholyticsStereotyped BehaviorNeurosciencemedicine.drugPharmacology Biochemistry and Behavior
researchProduct

Identification of potential therapeutic compounds for Parkinson's disease using Drosophila and human cell models.

2017

Abstract Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. It is caused by a loss of dopaminergic neurons in the substantia nigra pars compacta, leading to a decrease in dopamine levels in the striatum and thus producing movement impairment. Major physiological causes of neurodegeneration in PD are oxidative stress (OS) and mitochondrial dysfunction; these pathophysiological changes can be caused by both genetic and environmental factors. Although most PD cases are sporadic, it has been shown that 5–10% of them are familial forms caused by mutations in certain genes. One of these genes is the DJ-1 oncogene, which is involved in an early…

0301 basic medicineParkinson's diseaseProtein Deglycase DJ-1Drug Evaluation PreclinicalSubstantia nigraNerve Tissue ProteinsBiologymedicine.disease_causeBiochemistryAnimals Genetically Modified03 medical and health sciences0302 clinical medicineDopaminePhysiology (medical)Cell Line TumorDrug DiscoverymedicineAnimalsDrosophila ProteinsHumansGeneticsMutationPars compactaNeurodegenerationDopaminergicParkinson Diseasemedicine.diseaseDisease Models AnimalOxidative Stress030104 developmental biologyGene Knockdown TechniquesMutationCancer researchDrosophila030217 neurology & neurosurgeryOxidative stressLocomotionmedicine.drugFree radical biologymedicine
researchProduct